EGFR-tyrosine kinase inhibitors (TKIs) and neutralizing antibody (EGFR monoclonal antibodies) treatments can induce autophagy in multiple cancers, including glioblastoma, human vulvar squamous carcinoma, colorectal adenocarcinoma, and NSCLC cells [18,19]. Here, EGFR is linked to glioblastoma.